Screener
OrthoPediatrics KIDS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by OrthoPediatrics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: OrthoPediatrics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 1:56 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001425450-26-000070
FAQ
- What is OrthoPediatrics's cash & equivalents?
- OrthoPediatrics (KIDS) reported cash & equivalents of $19.06M in Q2 2026.
- How has OrthoPediatrics's cash & equivalents changed year-over-year?
- OrthoPediatrics's cash & equivalents decreased by 59.1% year-over-year, from $46.61M to $19.06M.
- What is the long-term trend for OrthoPediatrics's cash & equivalents?
- Over 5 years (2020 to 2025), OrthoPediatrics's cash & equivalents has grown at a -6.4% compound annual growth rate (CAGR), from $30.13M to $21.62M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about OrthoPediatrics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude